Difference between revisions of "Leiomyosarcoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
m |
||
| Line 5: | Line 5: | ||
=Adjuvant therapy= | =Adjuvant therapy= | ||
==Observation== | ==Observation== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 20: | Line 20: | ||
| style="background-color:#fc8d59" |Seems to have inferior DFS | | style="background-color:#fc8d59" |Seems to have inferior DFS | ||
|- | |- | ||
| − | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6241678/ Hensley et al. 2018 (GOG-0277)] |
|2012-2016 | |2012-2016 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| Line 27: | Line 27: | ||
|} | |} | ||
''No further treatment.'' | ''No further treatment.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*GOG-0277: [[Surgery#Hysterectomy|Hysterectomy]] | *GOG-0277: [[Surgery#Hysterectomy|Hysterectomy]] | ||
| + | </div></div> | ||
===References=== | ===References=== | ||
# '''SARCGYN:''' Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A; French Sarcoma Group. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Ann Oncol. 2013 Apr;24(4):1099-104. Epub 2012 Nov 8. [https://doi.org/10.1093/annonc/mds545 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23139262 PubMed] NCT00162721 | # '''SARCGYN:''' Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A; French Sarcoma Group. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Ann Oncol. 2013 Apr;24(4):1099-104. Epub 2012 Nov 8. [https://doi.org/10.1093/annonc/mds545 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23139262 PubMed] NCT00162721 | ||
| − | # '''GOG-0277:''' Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2018 Nov 20;36(33):3324-30. Epub 2018 Oct 5. [https://doi.org/10.1200/JCO.18.00454 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30289732 PubMed] NCT01533207 | + | # '''GOG-0277:''' Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2018 Nov 20;36(33):3324-30. Epub 2018 Oct 5. [https://doi.org/10.1200/JCO.18.00454 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6241678/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30289732 PubMed] NCT01533207 |
[[Category:Leiomyosarcoma regimens]] | [[Category:Leiomyosarcoma regimens]] | ||
Revision as of 04:01, 25 February 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main LMS page for current regimens.
Adjuvant therapy
Observation
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Pautier et al. 2012 (SARCGYN) | 2001-2009 | Phase 3 (C) | API | Seems to have inferior DFS |
| Hensley et al. 2018 (GOG-0277) | 2012-2016 | Phase 3 (C) | GD, then Doxorubicin | Did not meet primary endpoint of OS |
No further treatment.
Preceding treatment
- GOG-0277: Hysterectomy
References
- SARCGYN: Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A; French Sarcoma Group. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Ann Oncol. 2013 Apr;24(4):1099-104. Epub 2012 Nov 8. link to original article PubMed NCT00162721
- GOG-0277: Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2018 Nov 20;36(33):3324-30. Epub 2018 Oct 5. link to original article link to PMC article PubMed NCT01533207